KPIs & Operating Metrics(New)
Growth Metrics

AbbVie (ABBV) EBIT Margin (2012 - 2026)

AbbVie (ABBV) reported EBIT Margin of 26.6% for Q1 2026, down 138.0% year-over-year from 69.99% in Q1 2025, and down 2.73% on a QoQ basis from 27.34% in Q4 2025.

AbbVie (ABBV) has 15 years of EBIT Margin data on file, last reported at 26.6% in Q1 2026.

  • Quarterly EBIT Margin fell 138.0% year-over-year to 26.6% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 24.41% (up 685.0% YoY) and the FY2025 annual result came in at 24.65%, up 843.0% from the prior year.
  • EBIT Margin declined to 26.6% in Q1 2026 per ABBV's latest filing, from 27.34% in the prior quarter.
  • Across five years, EBIT Margin topped out at 36.39% in Q4 2022 and bottomed at 9.87% in Q4 2024.
  • The 5-year median for EBIT Margin is 26.6% (2026), against an average of 24.21%.
  • The widest annual swing landed in 2024, when EBIT Margin tumbled 3221 bps; it then surged 3721 bps in 2025.
  • Tracing ABBV's EBIT Margin over 5 years: stood at 36.39% in 2022, then plunged by 39 bps to 22.34% in 2023, then tumbled by 144 bps to 9.87% in 2024, then soared by 377 bps to 27.34% in 2025, then fell by 3 bps to 26.6% in 2026.
  • Per Business Quant, the three latest ABBV EBIT Margin figures stand at 26.6% (Q1 2026), 27.34% (Q4 2025), and 12.07% (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 47.98%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 26.44%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 26.60%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -47.46%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 30.94%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 37.16%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -286.83%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn -1.58%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 26.60%
Dec 31, 2025 27.34%
Sep 30, 2025 12.07%
Jun 30, 2025 31.73%
Mar 31, 2025 27.98%
Dec 31, 2024 -9.87%
Sep 30, 2024 26.49%
Jun 30, 2024 27.64%
Mar 31, 2024 22.73%
Dec 31, 2023 22.34%
Sep 30, 2023 16.38%
Jun 30, 2023 32.55%
Mar 31, 2023 22.64%
Dec 31, 2022 36.39%
Sep 30, 2022 31.08%
Jun 30, 2022 22.59%
Mar 31, 2022 34.84%
Dec 31, 2021 34.09%
Sep 30, 2021 30.02%
Jun 30, 2021 31.81%
Mar 31, 2021 31.54%
Dec 31, 2020 27.08%
Sep 30, 2020 25.23%
Jun 30, 2020 7.21%
Mar 31, 2020 41.80%
Dec 31, 2019 45.45%
Sep 30, 2019 30.86%
Jun 30, 2019 41.19%
Mar 31, 2019 38.45%
Dec 31, 2018 -29.39%
Sep 30, 2018 38.36%
Jun 30, 2018 33.37%
Mar 31, 2018 36.59%
Dec 31, 2017 23.03%
Sep 30, 2017 38.51%
Jun 30, 2017 38.34%
Mar 31, 2017 36.82%
Dec 31, 2016 34.05%
Sep 30, 2016 36.71%
Jun 30, 2016 -1.39%
Mar 31, 2016 38.23%
Dec 31, 2015 33.02%
Sep 30, 2015 31.71%
Jun 30, 2015 314.95%
Mar 31, 2015 33.47%
Dec 31, 2014 -7.61%
Sep 30, 2014 19.13%
Jun 30, 2014 30.76%
Mar 31, 2014 29.61%
Dec 31, 2013 30.03%
Sep 30, 2013 29.43%
Jun 30, 2013 30.97%
Mar 31, 2013 30.15%
Dec 31, 2012 34.98%
Sep 30, 2012 35.40%
Jun 30, 2012 31.65%
Mar 31, 2012 23.44%